Journal Section:
Commentary
References
1.
Heidenreich
PA
, Bozkurt
B
, Aguilar
D
, Allen
LA
, Byun
JJ
, Colvin
MM
, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines
. Circulation
. 2022
;145
(18
):e895
–1032
. 2.
Abassi
Z
, Khoury
EE
, Karram
T
, Aronson
D
. Edema formation in congestive heart failure and the underlying mechanisms
. Front Cardiovasc Med
. 2022
;9
:933215
. 3.
Peters
AE
, Mentz
RJ
, DeWald
TA
, Greene
SJ
. An evaluation of torsemide in patients with heart failure and renal disease
. Expert Rev Cardiovasc Ther
. 2022
;20
(1
):5
–11
. 4.
Wu
L
, Rodriguez
M
, El Hachem
K
, Krittanawong
C
. Diuretic treatment in heart failure: a practical guide for clinicians
. J Clin Med
. 2024
;13
(15
):4470
. 5.
Welzel
B
, Schmidt
R
, Kirchhoff
L
, Gramer
M
, Löscher
W
. The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia
. Epilepsy Behav
. 2023
;139
:109057
. 6.
Lo
KB
, Rangaswami
J
. Torsemide is a more appropriate oral loop diuretic for patients with heart failure: CON
. Kidney360
. 2024
;5
(8
):1069
–71
. 7.
Buggey
J
, Mentz
RJ
, Pitt
B
, Eisenstein
EL
, Anstrom
KJ
, Velazquez
EJ
, et al. A reappraisal of loop diuretic choice in heart failure patients
. Am Heart J
. 2015
;169
(3
):323
–33
. 8.
Kasama
S
, Toyama
T
, Hatori
T
, Sumino
H
, Kumakura
H
, Takayama
Y
, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure
. Heart
. 2006
;92
(10
):1434
–40
. 9.
Singh
S
, Goel
S
, Duhan
S
, Chaudhary
R
, Garg
A
, Tantry
US
, et al. Effect of furosemide versus torsemide on hospitalizations and mortality in patients with heart failure: a meta-analysis of randomized controlled trials
. Am J Cardiol
. 2023
;206
:42
–8
. 10.
Teixeira
L
, Felix
N
, Navalha
DDP
, Ferreira
R
, Clemente
MRC
, Madeira
T
, et al. Torsemide versus furosemide in the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials
. Arq Bras Cardiol
. 2024
;121
(6
):e20230825
. 11.
Mentz
RJ
, Anstrom
KJ
, Eisenstein
EL
, Sapp
S
, Greene
SJ
, Morgan
S
, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial
. JAMA
. 2023
;329
(3
):214
–23
. 12.
Kido
K
, Al-Mamun
M
. Evaluation of patients with heart failure with reduced ejection fraction treated with bumetanide versus torsemide
. Cardiology
. 2025
:1
–17
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended...
© 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.